Depo-Provera Lawsuits
Depo-Provera lawsuits claim brand name Depo-Provera birth control, or its generic forms, may increase the risk of rare brain tumors called meningiomas. Lawyers claim Pfizer didn’t properly warn about the risk. Litigation is in the early phases and there have been no settlements or jury verdicts yet.
Latest Depo-Provera Lawsuit Updates
As of August 2024, Depo-Provera lawsuits for brain tumors have just begun, and there haven’t been too many developments. Attorneys are accepting and investigating cases from people diagnosed with meningioma, a type of brain tumor, after using Depo-Provera or Depo-SubQ Provera birth control shots.
-
November 2024:
A motion has been filed for Depo-Provera lawsuits to be consolidated into multidistrict litigation in California. This would be a major step in the process of the litigation, but a decision on the motion could take several months.
-
August 2024:
So far, these cases are still in the early stages and lawyers are investigating claims. There has been no multidistrict litigation, and it’s still too early to tell if there will be one.
-
March 2024:
A March 2024 study published in British Medical Journal (BMJ) found women injected with the active ingredient in Depo-Provera, medroxyprogesterone acetate, had a 5.6-fold higher risk of developing meningioma. French researchers published their findings in March 2024.
Depo-Provera is commonly known as the birth control shot and contains the active ingredient medroxyprogesterone acetate, which is also available in generic form. Serious Depo-Provera side effects include significant bone density loss, slight increase in breast cancer risk and blood clots.
While there have been some other lawsuits filed for bone density loss and pseudotumor cerebri, there have been no significant developments in these litigations. This page focuses primarily on Depo Provera brain tumor lawsuits.
How to Qualify for a Depo-Provera Brain Tumor Lawsuit
To qualify for a Depo-Provera brain tumor lawsuit, claimants must meet specific criteria, including time limits for filing a claim (statutes of limitations), length of Depo-Provera use and a specific diagnosis.
- Use of brand name Depo-Provera, Depo-SubQ Provera or an authorized generic form of these birth control shots called medroxyprogesterone acetate
- Must have used Depo-Provera at least twice before brain tumor diagnosis
- Must have a diagnosis of meningioma after using Depo-Provera, Depo-SubQ Provera or a generic form of the birth control shot
- Depo-Provera, Depo-Provera, Depo-SubQ Provera or an authorized generic form use any time after 1992
These criteria are just general guidelines, and potential claimants should contact a lawyer to find out about their specific case.
Some potential claimants might not qualify depending on the laws of the state they live in. Make sure to contact an attorney right away to preserve the right to file a lawsuit.
Depo-Provera Brain Tumor Study
According to a March 2024 study published in BMJ, Depo-Provera is linked to a higher risk of developing meningioma, a type of noncancerous brain tumor. The risk increases with long-term use. After this study was published, lawyers began investigating cases.
“The study showed prolonged use of medrogestone, medroxyprogesterone acetate, and promegestone was found to be associated with an increased risk of meningioma. No excess risk of meningioma was associated with the use of progesterone, dydrogesterone, or spironolactone, or the hormonal intrauterine systems used worldwide, regardless of the dose of levonorgestrel they contained,” oncology clinical pharmacy specialist, Dazhi Liu, told Consumer Notice.
“The study showed prolonged use of…medroxyprogesterone acetate…was found to be associated with an increased risk of meningioma.”
The BMJ study is the first of its kind, and authors noted that compared to all birth control methods studied, medroxyprogesterone acetate increased more than other methods — a 5.6-fold increase in risk.
While meningiomas are not typically malignant, these tumors can affect nearby brain tissue, nerves and blood vessels and cause serious disability. When this happens, they must be surgically removed, and brain surgery may have serious risks.
“We are aware of this potential risk associated with long-term use of progestogens and, in collaboration with regulatory agencies, are in the process of updating product labels and patient information leaflets with appropriate wording,” Pfizer told the Guardian in a statement.
Depo-Provera Pseudotumor Cerebri and Bone Density Lawsuits
The most recent Depo-Provera lawsuits are for brain tumors, but earlier Depo-Provera litigation involved claims for pseudotumor cerebri and loss of bone mineral density. Consumer Notice’s partners are not currently accepting claims for pseudotumor cerebri or bone mineral density.
Pseudotumor Cerebri Lawsuits
Depo-Provera pseudotumor cerebri lawsuits claimed the birth control shot could cause a condition that occurs when pressure builds up in the brain, mimicking a tumor. Plaintiffs alleged that Pfizer didn’t warn birth control shot users about the risk.
Mirena lawsuits have also claimed the IUD could cause this condition. We aren’t aware of any publicly announced settlements or jury verdicts from Depo-Provera or Mirena litigation for this injury claim.
Bone Density Lawsuits
Depo-Provera bone density lawsuits alleged that Pfizer failed to warn that the birth control shot could lower bone density and lead to osteopenia and osteoporosis. Pfizer added a black box warning to Depo-Provera’s medication label in 2004 in the U.S.
In Canada, plaintiffs filed a Depo-Provera class action lawsuit in May 2008. According to the lawsuit, Pfizer misrepresented the risk of potentially irreversible bone mineral density loss in Depo-Provera users.
Pfizer paid $1,913,750 to the class and $262,500 to health insurance companies to settle claims in 2021.
Choosing a Depo-Provera Lawyer
We recommend choosing a Depo-Provera lawyer that has experience in handling pharmaceutical injury lawsuits against large corporations. For example, Consumer Notice’s legal partners spent decades seeking justice for plaintiffs against companies such as Johnson & Johnson, Bayer and Pfizer — the maker of Depo-Provera.
These firms have track records of negotiating settlements and winning jury verdicts in the billions. You can sign up for a free case review with an experienced product liability lawyer by signing up for a free case evaluation on Consumer Notice. Our legal partners will contact you and let you know if they can help.
6 Cited Research Articles
Consumernotice.org adheres to the highest ethical standards for content production and references only credible sources of information, including government reports, interviews with experts, highly regarded nonprofit organizations, peer-reviewed journals, court records and academic organizations. You can learn more about our dedication to relevance, accuracy and transparency by reading our editorial policy.
- Before the United States Judicial Panel on Multidistrict Litigation. (2024, November 26). Memorandum in Support of Motion For Transfer of Actions to the Northern District of California Pursuant to 28 USC § 1407 For Coordinated or Consolidated Pretrial Proceedings. Retrieved from https://ecf.jpml.uscourts.gov/doc1/85011465921
- DailyMed. (2024, July 26). DEPO-PROVERA- medroxyprogesterone acetate injection, suspension. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=199cf13e-0859-4a73-9b45-e700d0cd1049#S5.3
- Roland, N. et al. (2024, March 27). Use of progestogens and the risk of intracranial meningioma: national case-control study. Retrieved from https://www.bmj.com/content/384/bmj-2023-078078.long
- Sample, I. (2024, March 27). Hormone medication could increase risk of brain tumours, French study finds. Retrieved from https://www.theguardian.com/society/2024/mar/27/hormone-medication-brain-tumours-risk-progestogens-study
- Siskinds LLP. (2021, September 14). Settlement Agreement Reached in the Canadian Depo-Provera Class Action. Retrieved from https://www.newswire.ca/news-releases/settlement-agreement-reached-in-the-canadian-depo-provera-class-action-882468594.html
- Penn Medicine. (n.d.) Meningioma: What is Meningioma? Retrieved from https://www.pennmedicine.org/for-patients-and-visitors/patient-information/conditions-treated-a-to-z/meningioma
Calling this number connects you with a Consumer Notice, LLC representative. We will direct you to one of our trusted legal partners for a free case review.
Consumer Notice, LLC's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.
866-934-1922